For the quarter ending 2026-03-31, TNYA made $225K in revenue. -$19,272K in net income. Net profit margin of -8565.33%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 225 | - | - | - |
| Research and development | 14,843 | 19,508* | 15,363 | 17,370 |
| General and administrative | 5,447 | 6,297* | 5,573 | 6,712 |
| Total operating expenses | 20,290 | 25,804 | 20,936 | 24,082 |
| Loss from operations | -20,065 | -25,804* | -20,936 | -24,082 |
| Other income, net | - | 72* | 3 | -16 |
| Interest income | 793 | 473* | 658 | 815 |
| Total other income, net | 793 | 544* | 661 | 799 |
| Net loss before income tax expense | -19,272 | -25,260 | -20,275 | -23,283 |
| Net loss | -19,272 | -25,260* | -20,275 | -23,283 |
| Net unrealized (loss) gain on marketable securities | - | -43* | 1 | 9 |
| Comprehensive loss | -19,272 | -25,303 | -20,274 | -23,274 |
| Basic EPS | -0.09 | -0.191 | -0.12 | -0.14 |
| Diluted EPS | -0.09 | -0.191 | -0.12 | -0.14 |
| Basic Average Shares | 216,883,164 | 132,776,226 | 163,345,972 | 162,791,579 |
| Diluted Average Shares | 216,883,164 | 132,776,226 | 163,345,972 | 162,791,579 |
Tenaya Therapeutics, Inc. (TNYA)
Tenaya Therapeutics, Inc. (TNYA)